MRUS
Price
$44.37
Change
+$2.54 (+6.07%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
3.06B
18 days until earnings call
XENE
Price
$38.20
Change
+$0.61 (+1.62%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
2.81B
19 days until earnings call
Ad is loading...

MRUS vs XENE

Header iconMRUS vs XENE Comparison
Open Charts MRUS vs XENEBanner chart's image
Merus
Price$44.37
Change+$2.54 (+6.07%)
Volume$10.76K
Capitalization3.06B
Xenon Pharmaceuticals
Price$38.20
Change+$0.61 (+1.62%)
Volume$8.77K
Capitalization2.81B
MRUS vs XENE Comparison Chart
Loading...
MRUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MRUS vs. XENE commentary
Apr 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MRUS is a Buy and XENE is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 25, 2025
Stock price -- (MRUS: $41.78 vs. XENE: $37.55)
Brand notoriety: MRUS and XENE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MRUS: 216% vs. XENE: 98%
Market capitalization -- MRUS: $2.89B vs. XENE: $2.81B
MRUS [@Biotechnology] is valued at $2.89B. XENE’s [@Biotechnology] market capitalization is $2.81B. The market cap for tickers in the [@Biotechnology] industry ranges from $266.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MRUS’s FA Score shows that 1 FA rating(s) are green whileXENE’s FA Score has 2 green FA rating(s).

  • MRUS’s FA Score: 1 green, 4 red.
  • XENE’s FA Score: 2 green, 3 red.
According to our system of comparison, XENE is a better buy in the long-term than MRUS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MRUS’s TA Score shows that 5 TA indicator(s) are bullish while XENE’s TA Score has 6 bullish TA indicator(s).

  • MRUS’s TA Score: 5 bullish, 5 bearish.
  • XENE’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, XENE is a better buy in the short-term than MRUS.

Price Growth

MRUS (@Biotechnology) experienced а -0.31% price change this week, while XENE (@Biotechnology) price change was +11.16% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.94%. For the same industry, the average monthly price growth was -5.37%, and the average quarterly price growth was -12.15%.

Reported Earning Dates

MRUS is expected to report earnings on Jul 31, 2025.

XENE is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+7.94% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MRUS($3.07B) has a higher market cap than XENE($2.81B). MRUS YTD gains are higher at: 5.493 vs. XENE (-4.209). MRUS (-269.6M) and XENE (-276.74M) have comparable annual earnings (EBITDA) . XENE has more cash in the bank: 627M vs. MRUS (537M). XENE has less debt than MRUS: XENE (9.02M) vs MRUS (9.91M). MRUS has higher revenues than XENE: MRUS (36.1M) vs XENE (0).
MRUSXENEMRUS / XENE
Capitalization3.07B2.81B109%
EBITDA-269.6M-276.74M97%
Gain YTD5.493-4.209-131%
P/E RatioN/AN/A-
Revenue36.1M0-
Total Cash537M627M86%
Total Debt9.91M9.02M110%
FUNDAMENTALS RATINGS
MRUS vs XENE: Fundamental Ratings
MRUS
XENE
OUTLOOK RATING
1..100
418
VALUATION
overvalued / fair valued / undervalued
1..100
59
Fair valued
98
Overvalued
PROFIT vs RISK RATING
1..100
3231
SMR RATING
1..100
9260
PRICE GROWTH RATING
1..100
5756
P/E GROWTH RATING
1..100
1004
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MRUS's Valuation (59) in the Biotechnology industry is somewhat better than the same rating for XENE (98). This means that MRUS’s stock grew somewhat faster than XENE’s over the last 12 months.

XENE's Profit vs Risk Rating (31) in the Biotechnology industry is in the same range as MRUS (32). This means that XENE’s stock grew similarly to MRUS’s over the last 12 months.

XENE's SMR Rating (60) in the Biotechnology industry is in the same range as MRUS (92). This means that XENE’s stock grew similarly to MRUS’s over the last 12 months.

XENE's Price Growth Rating (56) in the Biotechnology industry is in the same range as MRUS (57). This means that XENE’s stock grew similarly to MRUS’s over the last 12 months.

XENE's P/E Growth Rating (4) in the Biotechnology industry is significantly better than the same rating for MRUS (100). This means that XENE’s stock grew significantly faster than MRUS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MRUSXENE
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
72%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
81%
Momentum
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
73%
MACD
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
75%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
75%
Advances
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 2 days ago
73%
Declines
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 21 days ago
74%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
74%
Aroon
ODDS (%)
Bearish Trend 2 days ago
73%
Bearish Trend 2 days ago
80%
View a ticker or compare two or three
Ad is loading...
MRUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MISAX15.93N/A
N/A
Victory Trivalent International Sm-Cp A
RWBEX61.02N/A
N/A
American Funds Capital World Gr&Inc R2E
VRREX18.01N/A
N/A
Virtus Duff & Phelps Real Estate Secs R6
MXEVX10.87N/A
N/A
Empower Core Strategies Intl Eq Inv
TSAMX12.52N/A
N/A
Thornburg Summit A

MRUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, MRUS has been loosely correlated with CGON. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if MRUS jumps, then CGON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MRUS
1D Price
Change %
MRUS100%
+6.05%
CGON - MRUS
45%
Loosely correlated
+3.81%
ACLX - MRUS
43%
Loosely correlated
+0.53%
RCKT - MRUS
41%
Loosely correlated
+4.06%
KRYS - MRUS
40%
Loosely correlated
+2.00%
XENE - MRUS
39%
Loosely correlated
+1.62%
More